RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Istanbul Turkey (2012)

Organization Overview

First Clinical Trial
2017
NCT02807220
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Atabay Kimya Sanayi Ticaret A.S. | Imuneks Farma ilac San. Tic. A.S. | Pharmactive Ilac Sanayi ve Tic A.S. | RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. | World Medicine ILAC SAN. ve TIC. A.S.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Malnutrition (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 11